| Severe Combined Immunodeficiency

Asceniv vs Octagam 5%

Side-by-side clinical, coverage, and cost comparison for severe combined immunodeficiency.

Deep comparison between: Asceniv vs Octagam Immune Globulin (Human) with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsOctagam Immune Globulin (Human) has a higher rate of injection site reactions vs Asceniv based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Octagam Immune Globulin (Human) but not Asceniv, including UnitedHealthcare

Category

Asceniv

Octagam Immune Globulin (Human)

At A Glance

RouteIV infusion

FrequencyEvery 3-4 weeks

ClassIgG replacement therapy

RouteIV infusion

FrequencyEvery 3-4 weeks

ClassIntravenous immunoglobulin (IVIG)

Indications

Congenital agammaglobulinemia
Common Variable Immunodeficiency
X-linked agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency

Congenital agammaglobulinemia
Common Variable Immunodeficiency
X-linked agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency

Dosing

Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 800 mg/kg IV every 3 to 4 weeks; start infusion at 0.5 mg/kg/min for the first 15 minutes and increase gradually up to 8 mg/kg/min if tolerated.

Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300-600 mg/kg IV every 3-4 weeks; adjust dose over time to achieve desired trough levels and clinical response.

Measles Exposure 400 mg/kg IV as soon as possible and within 6 days of exposure; increase to at least 530 mg/kg every 3-4 weeks if patient is at risk of future measles exposure.

Contraindications

Previous anaphylactic or severe systemic reaction to human immune globulin
IgA deficiency with antibodies to IgA and history of hypersensitivity

Acute severe hypersensitivity reaction to human immunoglobulin
IgA deficiency with antibodies against IgA and history of hypersensitivity
Acute hypersensitivity reaction to corn (product contains maltose derived from corn)

Drug Interactions

163View drug interactions

Adverse Reactions

Most common (>=5%) Headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, nausea

Postmarketing Apnea, ARDS, cyanosis, dyspnea, bronchospasm, cardiac arrest, vascular collapse, hypotension, coma, loss of consciousness, seizures, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, bullous dermatitis, pancytopenia, leukopenia, pyrexia, rigors, hepatic dysfunction, abdominal pain

Most common (>=5%) headache, nausea

Serious anaphylactic reactions, thromboembolic events, aseptic meningitis, hemolytic anemia

Postmarketing leukopenia, hemolytic anemia, anaphylactic shock, angioedema, cerebrovascular accident, myocardial infarction, pulmonary embolism, renal failure acute, transfusion-related acute lung injury

Pharmacology

ASCENIV is an intravenous immunoglobulin replacement therapy that provides a broad spectrum of neutralizing IgG antibodies against bacterial and viral pathogens and their toxins; IgG antibodies act as opsonins to increase phagocytosis and elimination of pathogens from the circulation.

Intravenous immunoglobulin G preparation that supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacteria and their toxins; restores abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Asceniv